After engineering our hyperstable FGF2-STAB, our protein pro team focused on stabilizing another member of the FGF protein family. Now, we’re happy to announce, that we’ve managed to create a hyperstable FGF10-STAB.
In collaboration with Loschmidt Laboratories we continue to use the latest computational tools to research haloalkane dehalogenases.
Learn more about how we made our hyperstable FGF2. The details explaining how our molecule can last up to an unbelievable 20 days at 37 degrees have been published and are online.
Enantis founder, Prof Jiri Damborsky, was awarded the Ceska Hlava prize in the category of Invention. The Ceska Hlava is the top Czech prize awarded to outstanding scientists.
Are you a molecular biologist who is interested in joining our Protein pro team? Click on the link below and let us know.
Are you a lab technician who is interested in joining our Protein pro team? Click on the link below and let us know.
Read more (in Czech only)
For achieving Deloitte’s high standards for innovation, showing great potential, and exceling in our field.
We proudly announce that Enantis launched a new website today. With launch of our new website, we are introducing our re-defined corporate identity and visuals. Our new logo consists of a simplified protein molecule. It reinforces our goal to use our expert know-how and computing tools to make the complicated process of protein engineering simpler and deliver you the results faster. We are your protein pro team.
We are happy to announce that Gabin de La Bourdonnaye joined our team as a foreign Ph.D. student under the Marie Curie Initial Training Network. Gabin will be working on modification of proteins for medical and biotechnological applications by directed evolution.
A new substance we’re working on at Enantis could help change how doctors heal wounds. Its researchers adjusted a specific growth protein that can help skin repair itself much faster than normal.
We succeeded in the European Business Champions League – H2020 SME Instrument phase 2. Among the thousands of applicants from all across Europe, Enantis was the only Czech company to receive both phase 1 and phase 2 grant. The company will receive more than €1 million to finance its preclinical trial study for its project, and will also benefit from business coaching.